InvestorsHub Logo
Followers 137
Posts 3718
Boards Moderated 0
Alias Born 05/10/2006

Re: None

Friday, 09/18/2020 10:31:56 AM

Friday, September 18, 2020 10:31:56 AM

Post# of 200280
LET THIS SINK IN: BioClonetics FINAL stage of development of a parent monoclonal antibody ("mAbs") (designated as Clone 3), which is non-toxic & has shown in initial in vitro testing 2 B Effective against More than 95% of ALL Strains & viral subtypes of HIV-1 against which it's been tested

BioClonetics INVITED by the National Science Foundation (NSF) 2 submit an application 4 funding 4 development of anti-SARS-Cov-2 monoclonal antibodies using its proprietary #Technology. Such application to the NSF & a corresponding application to the NIH R NOW PENDING

The Company is also looking to expand its medical advisory board with individuals that have direct experience taking medical products through the regulatory process and bringing them to market.